Versartis Garners $126,000,000 New Funding

  • Feed Type
  • Date
    3/21/2014
  • Company Name
    Versartis
  • Mailing Address
    275 Shoreline Drive Mountain View, CA 94065 USA
  • Company Description
    Versartis (NASDAQ: VSAR) is developing new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis has licensed the rights to three products (VRS-826, VRS-859, and VRS-317) from Amunix.
  • Website
    http://www.versartis.com
  • Transaction Type
    IPO
  • Transaction Amount
    $126,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds purposes are on file with company statements at the SEC.
  • M&A Terms